Zobrazeno 1 - 10
of 13
pro vyhledávání: '"LUNG-I CHENG"'
Autor:
Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng
Publikováno v:
Journal of Comparative Effectiveness Research. 11:193-202
Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned-survival model was developed from the Nat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3927c7614cbff90b7f5119112e1d3123
https://doi.org/10.2217/cer-2021-0201
https://doi.org/10.2217/cer-2021-0201
Autor:
LUNG-I CHENG1, DALE, JENNA2
Publikováno v:
Pharmaceutical Executive. Jul/Aug2024, Vol. 44 Issue 7/8, p24-25. 2p.
Autor:
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 10 (2017)
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reducti
Externí odkaz:
https://doaj.org/article/7f9fd7632f2a455c94947fb72b3ea045
Autor:
Kathleen Wilson, Erwin A. Aguilar, Thomas Reske, Carly J. Paoli, Machaon Bonafede, Nguyet Tran, William P. Hudson, Abir Abdo, Bradley S. Stolshek, Lung-I Cheng, James S. Campbell, Sean D. Barry, Charles A. Cefalu
Publikováno v:
The American Journal of the Medical Sciences. 350:357-363
Contemporary estimates of the prevalence of diagnosed osteoporosis among long-term care facility residents are limited.This chart review collected data between April 1, 2012 and August 31, 2013 for adult (age ≥ 30 years) residents of 11 long-term c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5654d1587f607830d05f7e375b34001a
https://doi.org/10.1097/maj.0000000000000562
https://doi.org/10.1097/maj.0000000000000562
Publikováno v:
Journal of the American Medical Directors Association. 16:341-348
Objectives Our primary objective was to describe the prevalence of osteoporosis (OP) diagnosis in nursing home residents (NHRs). Secondary objectives included assessment of pharmacologic therapies and risk of fracture in NHRs with OP, as well as diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07531ba52f3293d46307b81cc71d9b93
https://doi.org/10.1016/j.jamda.2015.01.073
https://doi.org/10.1016/j.jamda.2015.01.073
Aims: Utility values inform estimates of the cost-effectiveness of treatment for cardiovascular disease (CVD), but values can vary depending on the method used. The aim of this systematic literature review (SLR) was to explore how methods of elicitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff4a83b31fd0a578cd5565f993de737d
Publikováno v:
Diabetes, obesitymetabolism. 15(10)
Aim To compare ‘progression to insulin’ for three cohorts on oral antidiabetic medication combinations: metformin/sulphonylurea (Met/SU), metformin/thiazolidinedione (Met/TZD) and sulphonylurea/thiazolidinedione (SU/TZD). Methods Retrospective co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f46f5211adf8e896e39d49bd079806f
https://pubmed.ncbi.nlm.nih.gov/23531154
https://pubmed.ncbi.nlm.nih.gov/23531154
Autor:
Lung I. Cheng, Karen L. Rascati
Publikováno v:
Arthritis careresearch. 64(9)
Objective To evaluate the impact of Medicare Part D on medication utilization, drug expenditures, and medical expenditures in patients with arthritis. Methods This was a retrospective study using a national sample of 2,484 Medicare-eligible beneficia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8555121967ecc442857a9f9f80d5ef
https://pubmed.ncbi.nlm.nih.gov/22508663
https://pubmed.ncbi.nlm.nih.gov/22508663
Publikováno v:
Clinical therapeutics. 33(12)
Background Patients newly diagnosed with type 2 diabetes mellitus generally initiate therapy with either metformin [Met] or a sulfonylurea [SU] drug, followed by the addition of a second agent (Met, an SU drug, or a thiazolidinedione [TZD] drug) if t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2912e5ac74875df4d53dfc5c0128098
https://pubmed.ncbi.nlm.nih.gov/22101160
https://pubmed.ncbi.nlm.nih.gov/22101160
Publikováno v:
Clinical therapeutics. 31(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3d36bb3c9d5cbead7fd19d79e5dfb41
https://pubmed.ncbi.nlm.nih.gov/19695407
https://pubmed.ncbi.nlm.nih.gov/19695407